---
layout: default
title: Benazepril
description: "Benazepril çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 5 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 30
evidence_level: L5
indication_count: 5
---

# Benazepril

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>5</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Benazeprilï¼šå¾åŸç™¼æ€§é«˜è¡€å£“åˆ°æƒ¡æ€§è…è¡€ç®¡æ€§é«˜è¡€å£“

## ä¸€å¥è©±ç¸½çµ
<p class="key-answer" data-question="Benazepril å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Benazepril æ˜¯ ACE æŠ‘åˆ¶åŠ‘ï¼Œç”¨æ–¼æ²»ç™‚é«˜è¡€å£“ï¼ŒTxGNN é æ¸¬å…¶å°æƒ¡æ€§è…è¡€ç®¡æ€§é«˜è¡€å£“å’Œæƒ¡æ€§é«˜è¡€å£“è…ç—…æœ‰æ•ˆï¼Œä½†éœ€æ³¨æ„æ­¤é¡ç–¾ç—…ä½¿ç”¨ ACE æŠ‘åˆ¶åŠ‘çš„ç¦å¿Œç—‡ã€‚
</p>


## å¿«é€Ÿç¸½è¦½
| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é«˜è¡€å£“ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | malignant renovascular hypertensionã€malignant hypertensive renal diseaseã€pulmonary hypertension with unclear multifactorial mechanismã€pulmonary hypertension owing to lung disease and/or hypoxiaã€hypertensive disorder |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.65% |
| è­‰æ“šç­‰ç´š | L5 (åƒ…é æ¸¬ï¼Œéœ€è¬¹æ…è©•ä¼°) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 5 (æœ‰æ•ˆè¨±å¯è­‰) |
| å»ºè­°æ±ºç­– | Hold |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬éœ€è¦è¬¹æ…ï¼Ÿ
é›–ç„¶ ACE æŠ‘åˆ¶åŠ‘å°é«˜è¡€å£“å’Œè…è‡Ÿä¿è­·æœ‰æ˜ç¢ºæ•ˆç›Šï¼Œä½†åœ¨è…è¡€ç®¡æ€§é«˜è¡€å£“çš„æ‡‰ç”¨æœ‰é‡è¦é™åˆ¶ï¼š

**æ½›åœ¨ç›Šè™•ï¼š**
- æŠ‘åˆ¶è…ç´ -è¡€ç®¡å¼µåŠ›ç´ -é†›å›ºé…®ç³»çµ± (RAAS)
- æ¸›å°‘è¡€ç®¡é‡å¡‘å’Œçº–ç¶­åŒ–
- è…è‡Ÿä¿è­·ä½œç”¨

**é‡å¤§é¢¨éšªï¼š**
- **é›™å´è…å‹•è„ˆç‹¹çª„ç¦å¿Œ**ï¼šACE æŠ‘åˆ¶åŠ‘å¯èƒ½å°è‡´æ€¥æ€§è…è¡°ç«­
- **å–®åŠŸèƒ½è…åˆä½µè…å‹•è„ˆç‹¹çª„ç¦å¿Œ**ï¼šåŒæ¨£å¯èƒ½å°è‡´æ€¥æ€§è…è¡°ç«­
- æƒ¡æ€§é«˜è¡€å£“å¸¸ä¼´éš¨åš´é‡è…åŠŸèƒ½æå‚·ï¼Œéœ€è¬¹æ…è©•ä¼°

## è‡¨åºŠè©¦é©—è­‰æ“š
| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | æ”¶æ¡ˆäººæ•¸ | ä¸»è¦ç™¼ç¾ |
|----------|------|------|----------|----------|
| - | - | - | - | (ç„¡ç›¸é—œè‡¨åºŠè©¦é©—) |

## æ–‡ç»è­‰æ“š
| PMID | å¹´ä»½ | æ¨™é¡Œ | ç›¸é—œæ€§ |
|------|------|------|--------|
| - | - | (ç„¡ç›´æ¥é‡å°æ­¤é©æ‡‰ç—‡çš„æ–‡ç») | - |

## å°ç£ä¸Šå¸‚è³‡è¨Š
| è¨±å¯è­‰è™Ÿ | ä¸­æ–‡å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | æ•ˆæœŸ |
|----------|----------|------|--------------|------|
| è¡›ç½²è—¥è£½å­—ç¬¬056647è™Ÿ | ç´“å¿ƒè† å›Š | è† å›ŠåŠ‘ | æ±ç”Ÿè¯è£½è—¥ | 2026/07/21 |
| è¡›ç½²è—¥è£½å­—ç¬¬057325è™Ÿ | å£“è«¾æœ¬éŒ  | éŒ åŠ‘ | å°ç£æ±æ´‹è—¥å“ | 2027/08/10 |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬025881è™Ÿ | é¹½é…¸è²é‚£æ™®åˆ© | åŸæ–™è—¥ | é´»å‚‘è—¥å“ | 2027/12/28 |
| è¡›ç½²è—¥è£½å­—ç¬¬046742è™Ÿ | è«¾å£“éŒ  | éŒ åŠ‘ | æ±ç”Ÿè¯è£½è—¥ | 2029/12/24 |
| è¡›éƒ¨è—¥è£½å­—ç¬¬059395è™Ÿ | å¯å¾—å¯§è†œè¡£éŒ  | è†œè¡£éŒ  | ä¸­åœ‹åŒ–å­¸è£½è—¥ | 2026/12/09 |

## å®‰å…¨æ€§è€ƒé‡
- **Moderate äº¤äº’ä½œç”¨**ï¼š
  - Hydrocortisoneï¼šå¯èƒ½é™ä½é™å£“æ•ˆæœ
  - Alogliptin ç­‰é™è¡€ç³–è—¥ï¼šå¯èƒ½å¢å¼·ä½è¡€ç³–é¢¨éšª
  - å¤šç¨®å…¶ä»–è—¥ç‰©
- **ç‰¹æ®Šè­¦å‘Š**ï¼š
  - é›™å´è…å‹•è„ˆç‹¹çª„æ‚£è€…ç¦ç”¨
  - å–®åŠŸèƒ½è…åˆä½µè…å‹•è„ˆç‹¹çª„ç¦ç”¨
  - å­•å©¦ç¦ç”¨ (è‡´ç•¸é¢¨éšª)
  - è¡€ç®¡æ€§æ°´è…«é¢¨éšª

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šMany psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially duri...
- å»ºè­°ï¼šCaution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihype...

**é«˜é‰€é£Ÿç‰© (Food High in Potassium)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šModerate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors.  In some cases, affected patients were using a potass...
- å»ºè­°ï¼šIt is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake.  Particular attention should be paid to the potassium content of sal...



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive ...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patie...

**Angioedema** ğŸŸ¢ Minor
- The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE ...

**Bone Marrow Failure Disorders** ğŸŸ¢ Minor
- ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma....

**å¿ƒè‡Ÿè¡°ç«­ (Heart Failure)** ğŸŸ¢ Minor
- ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals,...

*å¦æœ‰ 3 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥
**æ±ºç­–ï¼šHold**
**ç†ç”±ï¼š** TxGNN çš„é æ¸¬åœ¨è—¥ç†å­¸ä¸Šæœ‰éƒ¨åˆ†åˆç†æ€§ï¼Œä½†è‡¨åºŠå¯¦å‹™ä¸Šï¼Œè…è¡€ç®¡æ€§é«˜è¡€å£“ï¼ˆç‰¹åˆ¥æ˜¯é›™å´è…å‹•è„ˆç‹¹çª„ï¼‰æ˜¯ ACE æŠ‘åˆ¶åŠ‘çš„ç›¸å°ç¦å¿Œç—‡ã€‚æƒ¡æ€§é«˜è¡€å£“çš„æ²»ç™‚éœ€è¦å¿«é€Ÿä¸”å¯æ§çš„è¡€å£“ä¸‹é™ï¼Œé€šå¸¸ä½¿ç”¨éœè„ˆæ³¨å°„é™å£“è—¥ç‰©ã€‚æ­¤é æ¸¬å¯èƒ½åæ˜  ACE æŠ‘åˆ¶åŠ‘å°é«˜è¡€å£“ç›¸é—œè…ç—…çš„ä¸€èˆ¬æ€§æ•ˆç›Šï¼Œè€Œéç‰¹å®šé©æ‡‰ç—‡å»ºè­°ã€‚
**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
1. é‡æ¸…é æ¸¬çš„è‡¨åºŠæƒ…å¢ƒï¼šæ˜¯å¦æŒ‡è…è¡€ç®¡æ€§é«˜è¡€å£“çš„è¡“å¾Œæˆ–ä»‹å…¥å¾Œç®¡ç†ï¼Ÿ
2. æ’é™¤é›™å´è…å‹•è„ˆç‹¹çª„å¾Œï¼Œæ‰å¯è€ƒæ…®ä½¿ç”¨
3. æƒ¡æ€§é«˜è¡€å£“æ€¥æ€§æœŸæ‡‰ä½¿ç”¨éœè„ˆé™å£“è—¥ç‰©ï¼Œå¾…ç—…æƒ…ç©©å®šå¾Œå†è€ƒæ…®å£æœ ACE æŠ‘åˆ¶åŠ‘
4. æ­¤é æ¸¬ä¸å»ºè­°ç›´æ¥ç”¨æ–¼è‡¨åºŠæ±ºç­–


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Homatropine Methylbromide]({{ "/drugs/homatropine_methylbromide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Isoleucine]({{ "/drugs/isoleucine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Alprostadil]({{ "/drugs/alprostadil/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tetrabenazine]({{ "/drugs/tetrabenazine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ibuprofen]({{ "/drugs/ibuprofen/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Benazeprilè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/benazepril/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_benazepril,
  title = {Benazeprilè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/benazepril/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
